Global Eczema Therapeutics Pipeline Review 2014 - 5 Companies & 6 Drug Profiles
M2 - 18 mins ago
Research and Markets (http://www.researchandmarkets.com/research/5txcp4/eczema_pipeline) has announced the addition of the "Eczema - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Eczema, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Eczema and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Merck & Co., Inc. - FAES Farma SA - China Biologic Products, Inc. - GlycaNova Norway AS - Immune Response BioPharma, Inc. Drug Profiles - bilastine - desloratadine - Drug for Atopic Dermatitis and Eczema - Varicella Hyperimmune Globulins - IR-444 - MM-1501 For more information visit http://www.researchandmarkets.com/research/5t...a_pipeline
Evacetrapib Report 2014 - Forecast and Market Analysis to 2023
M2 - 1 hr 53 mins ago
Research and Markets (http://www.researchandmarkets.com/research/6z85cw/evacetrapib) has announced the addition of the "Evacetrapib (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023" report to their offering. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially. In addition to Merck's anacetrapib, Eli Lilly will be vying for space in the cholesterol market with its own Phase III CETP inhibitor, evacetrapib. Like the researchers at Merck, the CETP inhibitor team at Eli Lilly believes they have learned from the torcetrapib and dalcetrapib clinical trial failures. As with any aspirational LDL-C treatment, Eli Lilly had to demonstrate the LDL-C lowering capacity of evacetrapib. Scope - Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for Aricept for the top seven countries from 2013 to 2023. - Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Disease Management 5 Competitive Assessment 6 Unmet Need and Opportunity - Therapies that Directly Treat Thrombogenic Atherosclerotic Plaques - Therapies that Treat Fibrotic Myocardium and Associated Comorbidities - LDL-C-Lowering Drugs for Statin-Intolerant, Refractory, or Non-Compliant Patients - Antidotes for New Oral Anticoagulants (NOACs) - Blood-Thinning Agents with Significantly Reduced Bleeding Risks 7 Pipeline Assessment 8 Evacetrapib 9 Appendix For more information visit http://www.researchandmarkets.com/research/6z...vacetrapib
Robbins Arroyo LLP: Acquisition of Sigma-Aldrich Corporation (SIAL) by Merck KGaA (MRK) May Not Be in Shareholders' Best Interests
GlobeNewswire - Tue Sep 23, 5:35PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Sigma-Aldrich Corporation by Merck KGaA. On September 22, 2014, the companies announced that Sigma-Aldrich and Merck signed a definitive merger agreement pursuant to which Merck will acquire all outstanding shares of Sigma-Aldrich for $140.00 per share in cash.
INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Sigma-Aldrich Corporation Regarding the Fairness of the Sale of the Company to Merck
Business Wire - Tue Sep 23, 11:14AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Sigma-Aldrich Corporation (NasdaqGS: SIAL) ("Sigma-Aldrich"
Herpes Zoster (Shingles) Therapeutics Pipeline Review 2014 - 7 Companies & 9 Drug Profiles
M2 - Tue Sep 23, 9:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7qstv6/herpes_zoster) has announced the addition of the "Herpes Zoster (Shingles) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Zoster (Shingles), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Zoster (Shingles) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - GlaxoSmithKline plc - Merck & Co., Inc. - Astellas Pharma Inc. - Foamix Ltd. - Arcion Therapeutics, Inc. - Epiphany Biosciences, Inc. - NAL Pharmaceuticals Ltd. Drug Profiles - amenamevir - GSK-1437173A - V-212 - FV-100 - valomaciclovir stearate - lidocaine - acyclovir - NAL-3221 - NAL-3223 For more information visit http://www.researchandmarkets.com/research/7q...pes_zoster
Stock Market News for September 23, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 9:10AM CDT
Growth worries in China and disappointing home sales data dragged down the benchmarks on Monday
Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical
Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien
PR Newswire - Tue Sep 23, 8:05AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Merck & Co., Inc. (NYSE: MRK), Medtronic, Inc. (NYSE: MDT), Amgen Inc. (NASDAQ: AMGN) and Covidien plc (NYSE: COV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6679-100free.
Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sigma-Aldrich Corporation. Concerning its Proposed Sale to Merck --SIAL
PR Newswire - Tue Sep 23, 8:00AM CDT
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against the Board of Directors of Sigma-Aldrich Corporation. ("Concur Technologies" or the "Company"
Ophthotech Corporation Names Michael G. Atieh as Executive Vice President and Chief Financial and Business Officer
Business Wire - Tue Sep 23, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that Michael G. Atieh has been named Executive Vice President, Chief Financial and Business Officer and Treasurer effective September 30, 2014. Mr. Atieh replaces Bruce A. Peacock, Chief Financial and Business Officer and Treasurer, who has notified the Company of his intention to retire effective September 30, 2014.
Soligenix Appoints Rasappa Arumugham, PhD, as Vice President of Biopharmaceutical Development
PR Newswire - Tue Sep 23, 6:00AM CDT
Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense, announced today that it has appointed Rasappa Arumugham, PhD, as its Vice President of Biopharmaceutical Development. Dr. Arumugham has over 25 years of diverse experience in biopharmaceutical research and development (R&D) in the areas of formulation research, analytical method development, quality control (QC), and manufacturing. He has a proven track record in development, scale-up, and technology transfer supporting commercialization of vaccines and biologics, including Prevnar®, TetramuneTM, HibTITER®, Meningitec® Conjugate and meningitis B (bivalent rLP2086) Lipoprotein Subunit Vaccines.
Research and Markets: Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
Business Wire - Tue Sep 23, 3:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b9xlc3/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering.
Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry
M2 - Tue Sep 23, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2276th/global) has announced the addition of the "Global Pneumococcal Vaccines Market 2014-2018" report to their offering. The Global Pneumococcal Vaccines market to grow at a CAGR of 4.9% over the period 2013-2018 Pneumococcus (Streptococcus pneumonia), a pathogenic bacterium, is the leading cause of serious illness across the globe. It is the main cause of pneumonia, sinusitis, blood infections, meningitis, and middle ear infections (otitis media). Pneumococcal disease affects children and the elderly, and it is one of the leading infectious diseases worldwide. It kills almost 1.6 million people (including more than 800,000 children under the age five years) every year. Pneumococcal disease can be prevented by vaccination. Vaccination involves the introduction of dead or weakened antigen into the human body, which in turn produces lymphocytes to counter the infection and any future invasions by that antigen. One of the emerging trends in this market is strategic alliances of vendors in the market, resulting in consolidation. Such alliances are intended to increase the market penetration of the acquirer or to enhance the product portfolio of the parent company. According to the report, the major driving force in the market is the inclusion of the pneumococcal vaccination in the national immunization schedule of many countries, which helps to increase the consumption of vaccines in the market, thereby boosting growth. Further, the report states that the inadequate vaccine coverage in the world is a major challenge to the market growth, resulting in low reach of the vaccines in the market, which restrains growth. Key Vendors - GlaxoSmithKline - Merck - Pfizer Other Prominent Vendors - Lupin - Sanofi Pasteur MSD - S K Chemicals Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Product Type - Market Assessment of Top Pneumococcal Vaccines - Geographical Segmentation - Rate of Incidence and Prevalence - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/2276th/global
SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL
PR Newswire - Mon Sep 22, 7:28PM CDT
Levi & Korsinsky is investigating the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or "the Company"
Harwood Feffer LLP Announces Investigation of Sigma-Aldrich Corporation
PR Newswire - Mon Sep 22, 6:40PM CDT
Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Sigma-Aldrich Corporation And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Sep 22, 4:08PM CDT
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sigma-Aldrich Corporation ("Sigma-Aldrich" or the "Company"
Stock Market Today: Stocks End Lower but Top Not Yet In Sight, Analysts Say
at The Street - Mon Sep 22, 3:24PM CDT
U.S. stocks close lower on Monday while strategists say the slide is just a temporary blip and predict the market still has more legs.
Surprising Silver Lining for Gilead Sciences, inc. Stock
Brian Orelli, The Motley Fool - Motley Fool - Mon Sep 22, 2:37PM CDT
Shares of Gilead Sciences got knocked down last week after CVS Health released data showing higher discontinuation rates for hepatitis C patients taking Sovaldi than Gilead Sciences saw in its clinical trials. Source: Gilead Sciences ...
Why Jim Cramer Says Dresser-Rand (DRC), Sigma-Aldrich (SIAL), TRW (TRW) Acquisitions Are Important
at The Street - Mon Sep 22, 12:16PM CDT
TheStreet's Jim Cramer explains why German companies' acquisitions of Dresser-Rand (DRC), Sigma-Aldrich (SIAL) and TRW (TRW) are so important.
SIGMA-ALDRICH INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Sigma-Aldrich Corp. Over the Proposed Sale of the Company to Merck KGaA - SIAL
PR Newswire - Mon Sep 22, 12:08PM CDT
Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Sigma-Aldrich Corp. ("Sigma-Aldrich" or the "Company"